PAREXEL International Release: Perceptive Informatics(R) DataLabs(R) EDC Solution Ranks Highest in Overall Satisfaction

BOSTON, Nov. 29, 2011 /PRNewswire/ -- Perceptive Informatics^®, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), today announced that its DataLabs® Electronic Data Capture (EDC) solution ranked highest among EDC solutions for overall satisfaction in ISR’s 2011 The State of The EDC Market Report, an independent study conducted by Industry Standard Research (ISR). The DataLabs EDC solution enables clinical trial sponsors to more efficiently manage the clinical development process from study design to collection and reporting of study data.

ISR’s report, which is a comprehensive source for data on user experience with EDC solutions, surveyed 107 principal investigators and site coordinators in the biopharmaceutical industry. The respondents rated EDC solutions across five product attributes, as well as in overall satisfaction. In the ISR analysis of product attributes, the Perceptive Informatics DataLabs EDC solution ranked highest among EDC solutions for overall satisfaction, as well as in user interface and technical support. In the categories of integration capabilities and the process for dealing with queries, the report also ranked the DataLabs EDC solution as a top performer among its peer solutions.

“The high ratings Perceptive achieved for our DataLabs EDC solution reinforce our commitment to improve data quality, streamline workflows and deliver superior user experiences,” said Steve Kent, President, Perceptive Informatics. “We are pleased that the site leaders and staff using our technology are satisfied, and look forward to providing them with continual innovation to meet their evolving needs. This verification is testimony to the benefits realized by optimizing our EDC solution, and other solutions across our eClinical Suite, for the way users manage trials.”

Perceptive offers the DataLabs EDC solution as a software-as-a-service (SaaS) application, which is entirely hosted, maintained and supported by Perceptive’s quality-assured eClinical platform. Features of the DataLabs 5.0 EDC solution include a user-friendly interface, a powerful reporting engine, web-based study design tool and sophisticated search function, as well as advanced export functionality to easily extract EDC data. For more information about Perceptive’s DataLabs EDC solution visit: http://www.perceptive.com/edc/.

Information about ISR’s 2011 The State of The EDC and ePRO Market Report can be found at www.ISRreports.com.

About Perceptive Informatics

Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL, is focused on helping customers to accelerate the product development process through innovation. Perceptive enables customers to maximize the benefits of clinical trial technologies by providing flexible software-as-a-service (SaaS) applications and leading technology services. The Perceptive Informatics eClinical Suite is built on extensive medical and clinical expertise, as well as a deep understanding of the regulatory environment. The suite includes Randomization and Trial Supply Management (RTSM) technologies, Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO). The Perceptive Informatics eClinical Suite blurs the boundaries among systems that traditionally have been used in isolation, resulting in simplified workflow, improved efficiency and enhanced productivity. For more information about the integrated solutions in the Perceptive Informatics eClinical Suite visit www.perceptive.com.

About PAREXEL International

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 67 locations throughout 52 countries around the world, and has approximately 10,850 employees. For more information about PAREXEL International visit www.PAREXEL.com.

This release contains “forward-looking” statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated additional restructuring charges of approximately $4 million in the second quarter of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2011 as filed with the SEC on November 9, 2011, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged

SOURCE PAREXEL International Corporation